Disruptive Innovation: Opportunities and Implications for Lab Medicine

Chris Price

Christopher P. Price, PhD, FRCPath, FACB and
Andrew St John, PhD, MAACB

Disruptive Innovation: Opportunities and Implications for
Lab Medicine

September 
2010

Q&A Archive

Andrew St John

PRESENTATION

Disruptive innovation transforms complex and expensive services into simple and affordable services. New technologies (e.g., point-of-care testing and informatics) capture our knowledge of disease mechanisms and treatment strategies to enable more effective means of health care delivery. This Expert Access session will explore the concepts and their applications to different health care systems.

 

BIOGRAPHY

Christopher P. Price, PhD, FRCPath, FACB, is Visiting Professor in Clinical Biochemistry at the University of Oxford and Clinical Director of the Cumbria and Lancashire Pathology Commissioning Network. He is a member of the Horizon Scanning Group in the Department of Primary Care at the University of Oxford. He also works as an independent consultant in the field of diagnostics and laboratory medicine.

He trained as a clinical biochemist in the United Kingdom, holding senior positions in Southampton and Cambridge before becoming Professor of Clinical Biochemistry at the St Bartholomew’s and Royal London School of Medicine and Dentistry in London. In 2002 he moved to a position as Vice President of Outcomes Research for the Diagnostics Division of Bayer HealthCare, a position he held for four years.

He has held several positions in the Association for Clinical Biochemistry including Chairman and President, as well as being a member of the Board of Directors of AACC. He is currently a member of AACC’s EBM Committee. He has also been an adviser to the U.K. government on a number of occasions, being involved in two major reviews of laboratory medicine services.

His interests are primarily in evidence based laboratory medicine, point-of-care testing, disruptive innovation, change management and clinical leadership. He has published several papers, as well as co-editing and co-authoring books, on these topics.

Andrew St John, PhD, MAACB, trained as a clinical biochemist, having worked in laboratories in various parts of the world including the UK and Australia. Since joining the IVD industry he has worked in Australia, Asia and Europe for various companies including AVL, Roche Diagnostics and now Ortho Clinical Diagnostics. Dr. St John has also worked as a freelance consultant to the diagnostic industry providing scientific marketing and business development to clients that include established and start-up IVD companies as well as laboratories and academic organisations.

His interests include point-of-care testing, evidence based medicine and process excellence, subjects on which he has written papers, co-authored several books and served on national and international committees.

He has played an active role within the laboratory medicine profession, particularly within the Australasian Association of Clinical Biochemists where he has served on the Executive, been instrumental in the establishment of Lab Tests Online Australasia and is currently managing a federal government funded project to establish the national Point-of-Care Testing Practitioners Network.

He is now the Asia Pacific Regional Business Development Manager for Ortho Clinical Diagnostics and located in Perth, Australia.

 

Page Access: